|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400088847 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-28 08:23:59 |
|
注册时间: Date of Registration: |
2024-08-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
前瞻性多中心孕期疾病多组学研究项目 |
|
Public title: |
Prospective multi-center multi-omics study of diseases in pregnancy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
前瞻性多中心孕期疾病多组学研究项目 |
|
Scientific title: |
Prospective multi-center multi-omics study of diseases in pregnancy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
龚娥 |
研究负责人: |
漆洪波 |
|
Applicant: |
E Gong |
Study leader: |
Hongbo Qi |
|
申请注册联系人电话: Applicant telephone: |
+86 138 8341 2049 |
研究负责人电话: Study leader's telephone: |
+86 23 6380 9721 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
858307510@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
qihongbo728@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝北区龙山路120号 |
研究负责人通讯地址: |
重庆市渝北区龙山路120号 |
|
Applicant address: |
No. 120, Longshan Rd,Yubei District, Chongqing, China(401147) |
Study leader's address: |
No. 120, Longshan Rd,Yubei District, Chongqing, China(401147) |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆市妇幼保健院 |
||
|
Applicant's institution: |
Chongqing Health Center for Women and Children |
||
|
研究负责人所在单位: |
重庆市妇幼保健院 |
||
|
Affiliation of the Leader: |
Chongqing Health Center for Women and Children |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2022)伦审(科)038号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆市妇幼保健院伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of Chongqing Health Center for Women and Children |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-11-10 00:00:00 |
||
|
伦理委员会联系人: |
贺凌云 |
||
|
Contact Name of the ethic committee: |
Lingyun He |
||
|
伦理委员会联系地址: |
重庆市渝北区龙山路120号 |
||
|
Contact Address of the ethic committee: |
No. 120, Longshan Rd,Yubei District, Chongqing, China(401147) |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6331 6835 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chongqing Health Center for Women and Children |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝北区龙山路120号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 120, Longshan Rd,Yubei District, Chongqing, China(401147) |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
石家庄华大医学检验实验室有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shijiazhuang Huada Medical Laboratory Co., Ltd |
||||||||||||||||||||||
|
Target disease: |
Diseases in pregnancy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.建立2万孕妇多维度高质量的孕期疾病队列。针对子痫前期和早产筛查模型进行多中心临床研究,并完成筛查准确性评价。 2.通过多组学大数据研究,揭示子痫前期、早产、妊娠糖尿病、胎儿生长受限等生育健康疾病的新的生物标记物。 3. 综合遗传与环境风险因素,建立预测模型,为子痫前期、早产、妊娠糖尿病等疾病的风险预测以及个性化治疗提供基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To establish a multi-dimensional and high-quality pregnancy disease cohort of 20,000 pregnant women. A multi-center clinical study was conducted on screening models for preeclampsia and preterm birth, and evaluating the screening accuracy. 2. To reveal new biomarkers for reproductive health diseases such as preeclampsia, preterm birth, gestational diabetes, and fetal growth restriction through a multi-omics big data research. 3. To establish a prediction model by integrated genetic and environmental risk factors, in order to provide a basis for risk prediction and personalized treatment of preeclampsia, preterm birth, gestational diabetes and other diseases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 单胎,年龄18-45岁; 2. 孕妇在辖区内有固定住所; 3. 孕期在本院进行产检,并计划在本院分娩。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Singleton; age 18-45 years old; 2. The one who has a fixed residence in the city where she receives antenatal care; 3. The object of study shall have prenatal examinations during pregnancy and plan to give birth in the recruitment and research settings. |
||||||||||||||||||||||
|
排除标准: |
1. IVF孕妇; 2. 双胎或多胎孕妇; 3. 严重的心肝肾功能不全;自身免疫性疾病、恶性肿瘤疾病患者; 4. 多倍体、或较大胎儿缺陷,或24周前终止妊娠、流产或胎儿死亡; 5. 孕妇孕20周后失访,缺失临床信息和分娩结局。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. IVF pregnancy; 2. Pregnant women with twins or multiplets; 3. Patients with severe cardiac, liver and renal insufficiency; Patients with autoimmune diseases and malignant tumor diseases; 4. Polyploid, or large foetal defects, or termination of pregnancy, miscarriage or foetal death before 24 weeks; 5. Pregnant women were not followed up after 20 weeks of pregnancy, lacking clinical information and delivery outcomes. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-01 00:00:00至 To 2027-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-12-01 00:00:00 至 To 2027-12-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
https://api.bge.genomics.cn/adm-pl/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
https://api.bge.genomics.cn/adm-pl/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.利用线上问卷系统采集孕妇一般信息和既往病史等信息; 2.产后统一使用孕期疾病项目临床信息收集表,通过医院病历系统采集各个医院所入组孕妇各个疾病的详细临床病史和出院诊断。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. The online questionnaire system is used to collect the general information and past medical history of participants; 2. The clinical information collection table for diseases during pregnancy was used uniformly after delivery, and the detailed clinical history and discharge diagnosis of all diseases of pregnant women enrolled in each hospital shall be collected through the hospital medical record system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |